I am not angry. I am making a decision based on the information I have in front of me. If you look at who I am blaming for my losses in my last post it is myself. I bought into the hyperbole and I am paying for it. It goes to show that you are never too old to learn old lessons. What I recall are delays in filings, the EMEA delay in acceptance in only one part of the indication (surgery not childbirth), the inclusion of upfront in the 2007 4Q for a deal that did not happen,the partner who backed out, insider selling going into the Ovation deal closing, Russel index delisting occurring at the same time as the Ovation partnership deal announcement, hype regarding imminent FOB partnering, no sales in Europe for Atryn, the poorly chosen partner (LEO), the inadequate upfronts, the list goes on and IMO is stark evidence that I chose to ignore. Clearly not all of them are in the control of management but the pattern is a poor one. DD has posted on this board and on others deals done by other biotech companies in 2007 and early 2008 that gave them cash to continue through this current environment. GTC failed to get the cash when cash was available. Hindsight is 20/20 but prudent management would not have left the company with less than a year of cash on the hopes of signing FOB deals. As to the EMEA/FDA regulators, that is the business environment that all the biotechs operate not just GTCB.
You disagree with me and are perfectly entitled to do so. I have recently decided to take the loss and start selling down my position to a more prudent amount. I am entitle to vote those shares and then to sell them. I am not looking to impress anyone with my style as Dr. Cox apparently is but I think the last deal is very bad for existing shareholders and voted the shares I own/owned accordingly.
AI
Market Data 
Markets 
